Publications by authors named "John E Ray"

Claim this Profile
U
Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing.
Michael J Dolton, Gerd Mikus, Johanna Weiss, John E Ray, Andrew J McLachlan

J Antimicrob Chemother· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An audit of a therapeutic drug monitoring service for allopurinol therapy.
Diluk R W Kannangara, Sheena N Ramasamy, John E Ray, Graham Jones, Garry G Graham

Ther Drug Monit· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intraperitoneal voriconazole in a patient with Aspergillus peritoneal dialysis peritonitis.
Darren M Roberts, Geoffrey Kauter, John E Ray, Adrian G Gillin

Perit Dial Int· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Telaprevir and boceprevir: a potential role for therapeutic drug monitoring.
Michael J Dolton, John E Ray, Andrew J McLachlan

Ther Drug Monit· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antifungal use and therapeutic monitoring of plasma concentrations of itraconazole in heart and lung transplantation patients.
Jonathan Brett, OiFong Chong, Garry G Graham, John E Ray, Deborah Marriott

Ther Drug Monit· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration.
Michael J Dolton, John E Ray, Sharon C-A Chen, Kingsley Ng, Lisa Pont

Antimicrob Agents Chemother· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring.
Michael J Dolton, John E Ray, Sharon C-A Chen, Kingsley Ng, Lisa G Pont

Antimicrob Agents Chemother· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring.
Michael J Dolton, John E Ray, Deborah Marriott, Andrew J McLachlan

Antimicrob Agents Chemother· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized study of pharmacokinetics, efficacy, and safety of 2 raltegravir plus atazanavir strategies in ART-treated adults.
Dianne Carey, Sarah L Pett, Mark Bloch, Handan Wand, Karen MacRae, John E Ray

J Acquir Immune Defic Syndr· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical pharmacokinetics of metformin.
Garry G Graham, Jeroen Punt, Manit Arora, Richard O Day, Matthew P Doogue, John E Ray

Clin Pharmacokinet· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current status of therapeutic drug monitoring in Australia and New Zealand: a need for improved assay evaluation, best practice guidelines, and professional development.
Ross L Norris, Jennifer H Martin, Erin Thompson, John E Ray, Robert O Fullinfaw, Raymond G Morris

Ther Drug Monit· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correlation between HIV-1 RNA load in blood and seminal plasma depending on antiretroviral treatment status, regimen and penetration of semen by antiretroviral drugs.
Derek J Chan, John E Ray, Leon McNally, Marijka Batterham, Don E Smith

Curr HIV Res· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mild clinical toxicity and dose-dependent pharmacokinetics following acute lopinavir/ritonavir poisoning in a HIV-positive patient.
Darren M Roberts, John E Ray, Nick A Buckley

AIDS· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantification of antiretroviral drugs for HIV-1 in the male genital tract: current data, limitations and implications for laboratory analysis.
Derek J Chan, John E Ray

J Pharm Pharmacol· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CEDIA mycophenolic acid assay compared with HPLC-UV in specimens from transplant recipients.
Ian S Westley, John E Ray, Raymond G Morris

Ther Drug Monit· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Decision support tool to individualize cyclosporine dose in stable, long-term heart transplant recipients receiving metabolic inhibitors: overcoming limitations of cyclosporine C2 monitoring.
John E Ray, Anne M Keogh, Andrew J McLachlan

J Heart Lung Transplant· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic.
John E Ray, Debbie Marriott, Mark T Bloch, Andrew J McLachlan

Br J Clin Pharmacol· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cyclosporin C(2) and C(0) concentration monitoring in stable, long-term heart transplant recipients receiving metabolic inhibitors.
John E Ray, Anne M Keogh, Andrew J McLachlan, Fatemah Akhlaghi

J Heart Lung Transplant· July 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cyclosporin monitoring in Australasia: 2002 update of consensus guidelines.
Raymond G Morris, Kenneth F Ilett, Susan E Tett, John E Ray, Robert O Fullinfaw

Ther Drug Monit· December 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis